rozita mohd, noor syazwani izyan abdul rahaman, lydia kamaruzaman, wan rohaslizan wan daud, muhammad yusuf abu shamsi, lim kuan yee, ruslinda mustafar, abdul halim abdul gafor and syahrul sazliyana shaharir.  (2026).  clinical and biochemical factors associated with delayed renal response in proliferative lupus nephritis: a 20-year single-center multiethnic cohort study.  - biomedicines.  1 - 14. 

 

yusra hashim, siti nur hakimah hashim, kuan yee lim, nur ezzaty mohammad kazmin, muhammad yusuf abu shamsi, lydia kamaruzaman, rozita mohd.  (2025).  hypereosinophilic syndrome masquerading as a dialyzer reaction: a great mimicker.  - medical journal of bakirkoy.  339 - 342. 

 

noor muslia ahmad mustafa, rozita mohd, salihah muda.  (2025).  hemophagocytic lymphohistiocytosis following peritoneal dialysis-associated peritonitis with neurological involvement: a case report.  - journal of clinical and translational nephrology.  286 - 286. 

 

lim kuan yee, theepa nesam mariamutu, rozita mohd, norlaila mustafa, norfazilah ahmad, abdul halim abdul gafor.  (2025).  the effects of glucose containing haemodialysis dialysate on blood glucose and blood pressure.  - kidney international reports.  432 - 433. 

 

lim kuan yee, ahmad faiq sa'dan mohd zaini, rozita mohd.  (2025).  the role of neutrophil-lymphocyte and platelet-lymphocyte ratio as a predictor of relapse in lupus nephritis.  - kidney international reports.  192 - 193. 

 

rozita mohd, noor syazwani izyan abdul rahaman, lydia kamaruzaman, wan rohaslizan wan daud, muhammad yusuf abu shamsi, lim kuan yee, ruslinda mustafar, abdul halim abdul gafor and syahrul sazliyana shaharir.  (2026).  clinical and biochemical factors associated with delayed renal response in proliferative lupus nephritis: a 20-year single-center multiethnic cohort study.  - biomedicines.  1 - 14. 

 

junwen zhou,...empa kidney colloborative group, rizna abdul cader, ruslinda mustafar, lydia kamaruzaman, rozita mohd, rahimah ismail.  (2025).  effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the empa-kidney trial.  - eclinicalmedicine.  1 - 12. 

 

muhammad yusuf abu shamsi, rozita mohd, mohd shawal faizal mohamad, nazarudin safian, mohd asyiq rafali, lim kuan yee, wan rohaslizan wan daud.  (2025).  prevalence and risk factors of intradialytic hypertension in malaysian haemodialysis patients: a mutli-centre observational study.  - kidney international reports.  396 - 397. 

 

lim kuan yee, theepa nesam mariamutu, rozita mohd, norlaila mustafa, norfazilah ahmad, abdul halim abdul gafor.  (2025).  the effects of glucose containing haemodialysis dialysate on blood glucose and blood pressure.  - kidney international reports.  432 - 433. 

 

lim kuan yee, ahmad faiq sa'dan mohd zaini, rozita mohd.  (2025).  the role of neutrophil-lymphocyte and platelet-lymphocyte ratio as a predictor of relapse in lupus nephritis.  - kidney international reports.  192 - 193. 

 

fatimah zanirah nordin, syahrul sazliyana shaharir, mohd shahrir mohamed said, rozita mohd, rajalingham sakthiswary, tengku amatullah madeehah tengku mohd, mohd hafiz jaafar and wong chin yew.  (2024).  health seeking behaviour and diagnostic delays in sle: a multi-ethnic malaysian cohort study.  - lupus.  1645 - 1653. 

 

chua siew huoy ; teh cheng lay ; shaharir syahrul sazliyana ; ng chun ruh ; mohamed ismail asmahan ; ariff hairul hadi ;mohd salleh anna farazillah ; mohd asmah; ramlan azwarina ; wan mohamad akbar sharifah aishah ; tan cl; selvananda shakira ; maulana suhaida ; mageswaren eashwary ; wan ghazali w ;baharuddin h ; abd manaf n ; kan s ; mat husin n ; ling g ;goh c ; wan musa w ; mohd isa l; shahril n ; zainuddin n;ch'ng s; mohd zain m; mohammed yusoof h; abu mansor matardiah h ; ab rahim s ; gan s ; mohamed said m ; mohd r .  (2024).  diversity in the initial manifestations of systemic lupus erythematosus (sle) in malaysia.  - international journal of rheumatic diseases.  79 - 80. 

 

thu-ha nguyen, zulfitri azuan mat daud, ruzita abd. talib, rozita mohd, bee koon poh.  (2023).  metabolic syndrome and dietary intake are associated with quality of life in kidney transplant recipients.  - transplantation proceedings.  2176-2182. 

 

ruslinda mustafar, khairun amalin mohd hishamuddin, rozita mohd, lydia kamaruzaman, wan haslina wan abdul halim, yong meng hsien, tan kuan sze, wan mimi diyana wan zaki, aziah ali and arbaiyah bain.  (2023).  retinal changes and cardiac biomarker assessment in relation to chronic kidney disease: a single centre study.  - bmc nephrology.  1-12. 

 

fatimah zaharah rosli, syahrul sazliyana shaharir, abdul halim abdul gafor, rozita mohd, azimatun n aizuddin, sabrizan osman.  (2022).  cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of malaysian lupus nephritis patients.  - lupus.  1138-1146. 

 

rozita mohd, noor syazwani izyan abdul rahaman, lydia kamaruzaman, wan rohaslizan wan daud, muhammad yusuf abu shamsi, lim kuan yee, ruslinda mustafar, abdul halim abdul gafor and syahrul sazliyana shaharir.  (2026).  clinical and biochemical factors associated with delayed renal response in proliferative lupus nephritis: a 20-year single-center multiethnic cohort study.  - biomedicines.  1 - 14. 

 

emelia osman, rahmah noordin, rozita mohd, lydia kamaruzaman, siti nor azreen abdul manap, s. izuddin mohd. zali, nur afrina azhar, nor suhada anuar .  (2025).  strongyloides seroprevalence in patients with advanced chronic kidney disease at a tertiary hospital in malaysia: epidemiological profiles and comparison of two assays.  - parasite epidemiology and control.  1 - 8. 

 

junwen zhou,...empa kidney colloborative group, rizna abdul cader, ruslinda mustafar, lydia kamaruzaman, rozita mohd, rahimah ismail.  (2025).  effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the empa-kidney trial.  - eclinicalmedicine.  1 - 12. 

 

muhammad yusuf abu shamsi, rozita mohd, mohd shawal faizal mohamad, nazarudin safian, mohd asyiq rafali, lim kuan yee, wan rohaslizan wan daud.  (2025).  prevalence and risk factors of intradialytic hypertension in malaysian haemodialysis patients: a mutli-centre observational study.  - kidney international reports.  396 - 397. 

 

lim kuan yee, theepa nesam mariamutu, rozita mohd, norlaila mustafa, norfazilah ahmad, abdul halim abdul gafor.  (2025).  the effects of glucose containing haemodialysis dialysate on blood glucose and blood pressure.  - kidney international reports.  432 - 433. 

 

rozita mohd, fatimah zanirah nordin, rizna cader.  (2022).  assessment of chronic inflammatory demyelinating polyneuropathy in systemic lupus erythematosus.  - 150-157. 

 

syahrul sazliyana shaharir , nor adzimah johdi , rozita mohd.  (2022).  monoclonal antibody.  - 741-754. 

 

syahrul sazliyana shaharir, nor adzimah johdi, rozita mohda.  (2021).  monoclonal antibody.  - 1-10. 

 

ruslinda mustafar, lydia kamaruzaman, beh hui chien, azyani yahaya, noor'ain mohd nasir, rozita mohd, rizna cader, kong wei yen.  (2019).  a rare cause of acute kidney injury: primary renal lymphoma in a patient with human immunodeficiency virus.  - 2-13. 

 

ismail saibon, raha abdul rahman, nurismah md isa, leelavathi a/p muthupalaniappen, rozita mohd, mawaddah azman, shamsuriani md jamal.  (2019).  garis panduan peperiksaan klinikal (doktor pakar klinikal) fakulti perubatan universiti kebangsaan malaysia.  - 1-46. 

 

rozita mohd.  (2019).  langkah-langkah mudah untuk memastikan buah pinggang anda sihat.  - nadi diabetes.  40-41. 

 

lim kuan yee, wan haslina wan hassan, wan khadijah abd rahman, nor husa azlida husim, noorhazila baharudin, rozita mohd.  (2025).  role of neutrophil-to-lymphocyte ratio in peritoneal dialysis peritonitis.  - 11th asia pacific chapter meeting of the international society of peritoneal dialysis (apcm-ispd). 

 

muhammad yusuf abu shamsi assad khaleed theepa nesam mariamuthu lim kuan yee lydia kamaruzaman rozita mohd.  (2024).  difficulties in managing diffuse alveolar haemorrhage in systemic lupus erythematosus.  - asian pacific congress of nephrology. 

 

rozita binti mohd;abdul halim bin abdul gafor;rizna abdul cader;kong wei yen;ruslinda binti mustafar.  (2023).  phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (ndd-ckd) (pro2tect - conversion).  -

 

yong meng hsien;wan haslina binti wan abdul halim;rozita binti mohd;ruslinda binti mustafar;ayesha binti mohd zain.  (2023).  comparison of retinal optical coherence tomography angiography parameters between patients with different causes of chronic kidney diseases.  -

 

wan haslina binti wan abdul halim;rozita binti mohd;ruslinda binti mustafar;yong meng hsien;lydia binti kamaruzaman;ayesha binti mohd zain.  (2023).  comparison of optical coherence tomography angiography parameters between diabetic chronic kidney disease and non-diabetic chronic kidney disease.  -

 
Geran / Grant Kolaborator / Collaborator Status
A PIVOTAL PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF DMX-200 IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) WHO ARE RECEIVING AN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) iqvia rds malaysia sdn. bhd.
52% (2024-01-04 sehingga 2028-06-03)
A PHASE II RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, INTERNATIONAL TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF VICADROSTAT AND EMPAGLIFLOZIN ADMINISTERED WITH SIMULTANEOUS VS STAGGERED INITIATION IN PARTICIPANTS WI boehringer ingelheim (malaysia) sdn bhd
41.2% (2025-06-26 sehingga 2027-06-25)
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN PARTICIPANTS WITH PRIMARY MEMBRANOUS NEPHROPATHY (PMN) [PROMINENT] biogen idec research limited
14.6% (2025-11-13 sehingga 2028-11-12)
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY otsuka pharmaceutical development & commercialization, inc.
76.9% (2022-05-26 sehingga 2027-06-25)
A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED,EVENT-DRIVEN STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN ALONE ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY.. astrazeneca sdn. bhd.
21.9% (2025-02-20 sehingga 2030-06-19)

CLINICAL MEDICAL :CLINICAL AND HEALTH SCIENCES
Nephrology
Pengalaman / Experience : tahun/years(s)